TABLE 3.
Vestibular Fail |
|||||
---|---|---|---|---|---|
Covariate | Level | No (N=20) | Yes (N=30) | Odds Ratio | Parametric P-value* |
Gender | Male | 12 (42.86) | 16 (57.14) | 0.762 | 0.642 |
Female | 8 (36.36) | 14 (63.64) | |||
Diagnosis | Brain tumor | 8 (25.81) | 23 (74.19) | 4.929 | 0.009 |
No brain tumor | 12 (63.16) | 7 (36.84) | |||
Age at Diagnosis | Median (range) | 5.5 (0.7–15.4) | 7.0 (0.4–16.2) | 1.121 | 0.096 |
Brain surgery | No | 11 (57.89) | 8 (42.11) | 0.298 | 0.043 |
Yes | 9 (29.03) | 22 (70.97) | |||
Radiation to head/neck | No | 7 (46.67) | 8 (53.33) | 0.675 | 0.529 |
Yes | 13 (37.14) | 22 (62.86) | |||
Cisplatin | No | 15 (48.39) | 16 (51.61) | 0.381 | 0.122 |
Yes | 5 (26.32) | 14 (73.68) | |||
Carboplatin | No | 11 (30.56) | 25 (69.44) | 4.090 | 0.029 |
Yes | 9 (64.29) | 5 (35.71) | |||
Vancomycin | No | 16 (43.24) | 21 (56.76) | 0.375 | 0.247 |
Yes | 2 (22.22) | 7 (77.78) | |||
Aminoglycosides | No | 18 (41.86) | 25 (58.14) | 0.000 | 0.151 |
Yes | 0 (0) | 3 (100) | |||
Hearing loss | No | 12 (48.00) | 13 (52.00) | 0.451 | 0.228 |
Yes | 5 (29.41) | 12 (70.59) | |||
Years after total treatment | Median (range) | 5.9 (0.2–13.9) | 2.8 (0.2–10.6) | 0.812 | 0.018 |
The parametric p-value was calculated by univariate logistic regression (for Age at diagnosis and Years after total treatment) or chi-square test (for all others).